Figure 3.
Inhibition of cytokine production and costimulatory molecule expression by TLR9 antagonist CpG ODN 2088. Bone marrow–derived IPCs (5 × 105 cells/mL, 129/SvJ strain) were preincubated with increasing doses of the competitive TLR9 antagonist CpG ODN 2088 (0.04-2.5 μM) and then were cultured with HSV-1 (5 MOI), influenza virus PR8 (1 MOI), or medium alone for 24 hours. IFN-α and IL-12 were measured in the supernatants using ELISA. CD86 expression was determined by flow cytometry and is expressed as median fluorescence intensity after subtracting the background of the isotype control.
